INDRAMEDCO360.50

Indraprastha Medical Corporation Limited

· Pharma & Health
₹ CrorePeersARTEMISMEDSHALBYGKSLGPTHEALTHLOTUSEYEDRAGARWQKMCSHILKOVAIMcap ₹3,305 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth+9.0+9.3
EBITDA Growth+26.3+9.3
EBIT Growth+30.4+11.7
Net Income Growth+29.9+14.1
EPS Growth+29.9+14.1
Total Assets Growth+17.8+16.4
Total Equity Growth+24.9+24.1
Cash from Operations Growth-21.7+6.8
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.